mixed phenotype acute leukemia, B/myeloid
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:0081038
Name mixed phenotype acute leukemia, B/myeloid
Definition An acute biphenotypic leukemia that is characterized by blasts which express B-lymphoid and myeloid lineage markers but are negative for MLL translocation and t(9;22)(q34;q11.2) translocation.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute biphenotypic leukemia mixed phenotype acute leukemia, B/myeloid

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03643276 Phase III Daunorubicin + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Cyclophosphamide + Cytarabine + Dexamethasone + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab + Mercaptopurine + Methotrexate Bortezomib + Cyclophosphamide + Cytarabine + Dexamethasone + Mercaptopurine + Methotrexate + Pegaspargase + Vincristine Sulfate Cyclophosphamide + Cytarabine + Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Etoposide + Ifosfamide + Methotrexate + Pegaspargase + Vincristine Sulfate + Vindesine Blinatumomab + Cyclophosphamide + Cytarabine + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Blinatumomab Cytarabine + Daunoxome + Fludarabine + Methotrexate Cyclophosphamide + Cytarabine + Dexamethasone + Doxorubicin + Methotrexate + Pegaspargase + Thioguanine + Vincristine Sulfate Mercaptopurine + Methotrexate Asparaginase Erwinia chrysanthemi Daunorubicin + Dexamethasone + Methotrexate + Pegaspargase + Vincristine Sulfate Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 Recruiting SVK | ITA | ISR | DEU | CZE | CHE | AUT | AUS 0
NCT06317662 Phase II Blinatumomab Asparaginase Erwinia chrysanthemi + Cytarabine + Leucovorin + Mercaptopurine + Methotrexate + Venetoclax Cyclophosphamide + Cytarabine + Mercaptopurine + Venetoclax Mercaptopurine + Methotrexate Asparaginase Erwinia chrysanthemi + Cytarabine + Leucovorin + Mercaptopurine + Methotrexate Calaspargase pegol-mknl + Cytarabine + Daunorubicin + Dexamethasone + Thioguanine + Vincristine Sulfate Calaspargase pegol-mknl + Cytarabine + Daunorubicin + Dexamethasone + Vincristine Sulfate Calaspargase pegol-mknl + Daunorubicin + Dexamethasone + Venetoclax + Vincristine Sulfate Blinatumomab + Venetoclax Cyclophosphamide + Cytarabine + Mercaptopurine Blinatumomab + Dexamethasone Calaspargase pegol-mknl + Cyclophosphamide + Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Mercaptopurine + Methotrexate + Nelarabine + Venetoclax + Vincristine Sulfate Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Recruiting USA 1